These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35839690)

  • 1. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Blankenship L; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P3
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Blankenship L; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
    Kneller DW; Li H; Phillips G; Weiss KL; Zhang Q; Arnould MA; Jonsson CB; Surendranathan S; Parvathareddy J; Blakeley MP; Coates L; Louis JM; Bonnesen PV; Kovalevsky A
    Nat Commun; 2022 Apr; 13(1):2268. PubMed ID: 35477935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Poli ANR; Tietjen I; Nandwana NK; Cassel J; Messick TE; Register ET; Keeney F; Rajaiah R; Verma AK; Pandey K; Acharya A; Byrareddy SN; Montaner LJ; Salvino JM
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0056224. PubMed ID: 39225484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.
    Ghosh AK; Yadav M; Iddum S; Ghazi S; Lendy EK; Jayashankar U; Beechboard SN; Takamatsu Y; Hattori SI; Aamano M; Higashi-Kuwata N; Mitsuya H; Mesecar AD
    Eur J Med Chem; 2024 Mar; 267():116132. PubMed ID: 38335815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M
    Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
    bioRxiv; 2020 Jul; ():. PubMed ID: 32766590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
    Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
    ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
    Geng ZZ; Atla S; Shaabani N; Vulupala V; Yang KS; Alugubelli YR; Khatua K; Chen PH; Xiao J; Blankenship LR; Ma XR; Vatansever EC; Cho CD; Ma Y; Allen R; Ji H; Xu S; Liu WR
    J Med Chem; 2023 Aug; 66(16):11040-11055. PubMed ID: 37561993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
    Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
    Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.